During the past decade, Muhammad Irfan Malik conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Muhammad Irfan Malik" are "SARS-CoV Infection" (4 trials) and "SARS (Severe Acute Respiratory Syndrome)" (2 trials). Many other conditions were trialed in "Muhammad Irfan Malik" in a lesser frequency.

Most popular intervention types in "Muhammad Irfan Malik" are "Drug" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "High flow nasal cannula HFNC" (1 trials), "Methylprednisolone Injectable Product" (1 trials), "Remdesivir" (1 trials) and "convalescent plasma" (1 trials). Other intervention names were less common.

The vast majority of trials in "Muhammad Irfan Malik" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Muhammad Irfan Malik". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Muhammad Irfan Malik, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Muhammad Irfan Malik, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".